> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Axogen Will Start Prostate Nerve Repair Market Development In 2027, Citing Early Results From 220 Patients
- URL: https://www.bullished.co/axogen-will-start-prostate-nerve-repair-market-development-in-2027-citing-early-results-2c940db8/
- Published: 2026-10-28T13:16:15.000Z
- Updated: 2026-10-29T16:53:55.000Z
- Description: The company says about 80% of patients with six months of follow-up beat expected erectile recovery, and prostate sits outside its guidance.
- Author: Matteo Parrino
- Tags: Earnings, AXGN, Industry: Healthcare

[Axogen](https://www.bullished.co/tag/axgn/), which sells products surgeons use to repair damaged peripheral nerves, will begin market development for prostate nerve reconstruction in 2027, CEO Michael Dale said on the company's [earnings call](https://www.globenewswire.com/news-release/2026/10/28/3390038/0/en/axogen-inc-reports-third-quarter-2026-financial-results.html?ref=bullished.co) Wednesday. Over 220 patients have received the procedure with its Avance nerve graft across 15 clinical development sites, he said.

## Early outcomes from 117 patients

Dale said 117 of those patients have at least six months of follow-up: 86 grafted on one side and 31 on both. No graft or procedure-related complications were reported.

Among them, surgeons report that about 80% reached better than expected erectile function recovery, which Dale defined as a SHIM score of 15 or higher on a 25-point scale. Over 95% achieved pad-free urinary continence at or above expected levels. Dale said the results show "an exceptional benefit to risk ratio."

The baseline is weak. Dale said men undergoing unilateral non-nerve-sparing prostatectomy historically recover erectile function in only 33% to 56% of cases, and those undergoing bilateral procedures have less than a 13% chance.

## Targeting and margins

Asked by a Bank of America analyst how many of roughly 110,000 yearly robotic prostatectomies Axogen could target at launch, executive Jens said the company is building a targeting algorithm. It will focus on academic centers, high-volume centers and centers doing a mix of unilateral and bilateral reconstructions.

Dale said prostate grafts are shorter than breast grafts, so each donor yields more, and he does not expect the same margin pressure. CFO Lindsey Hartley said production benefits probably will not show up in 2027.

Dale said the value proposition is clearest for unilateral or bilateral non-nerve-sparing patients, and that broader groups such as active surveillance patients will come later.

## Outside guidance, with dates set

Dale said prostate is not in current or long-range guidance, and an update is planned for the first quarter of 2027\. The company will hold a prostate call on November 9 with two urologists, and will detail the financials and logistics of the plan at a March 2027 investor day.

The news came with [third-quarter results](https://seekingalpha.com/news/4658783-axogen-maintains-2026-revenue-outlook-of-at-least-290m-after-strong-q3?ref=bullished.co): revenue of $75.8 million, up 26.2% from a year earlier, and GAAP net income of $2.3 million. Hartley said 2026 revenue is now expected to be at least $290 million, including at least $7 million from BioCircuit, which Axogen bought on October 1\. The company had $350.1 million in cash and investments at September 30.

The November 9 call, with two urologists, is where Axogen has said it will lay out the clinical outcomes and market research behind the decision.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Axogen maintains 2026 revenue outlook of at least $290M after strong Q3 (AXGN:NASDAQ)](https://seekingalpha.com/news/4658783-axogen-maintains-2026-revenue-outlook-of-at-least-290m-after-strong-q3?ref=bullished.co) — seekingalpha.com
- [Axogen, Inc. Reports Third Quarter 2026 Financial Results](https://www.globenewswire.com/news-release/2026/10/28/3390038/0/en/axogen-inc-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com

### More on Axogen

- [Axogen Raised $225 Million In Stock Weeks Before Spending About $200 Million On BioCircuit](https://www.bullished.co/axogen-raised-225-million-in-stock-weeks-before-spending-about-200-million-on-biocircuit-d0cc8543/)
- [Axogen CFO Says $34 Million Nerve Tape Forecast Is Net Of Cannibalization](https://www.bullished.co/axogen-cfo-says-34-million-nerve-tape-forecast-is-net-of-cannibalization-541cd6e9/)
- [Axogen Lifts 2026 Revenue Outlook To At Least $290 Million After Third-Quarter Sales Climb 26.2%](https://www.bullished.co/axogen-lifts-2026-revenue-outlook-to-at-least-290-million-after-third-quarter-sales-climb-02735438/)

[All Axogen (AXGN) coverage →](https://www.bullished.co/tag/axgn/)